CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 168 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03317067
NCT03317067Phase 3Completed
CompareCT.gov

Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)

University Hospital, Clermont-Ferrand·interventional·Posted Oct 23, 2017·Updated May 13, 2026

In Brief

A Phase 3 clinical trial evaluating Dexmedetomidine and Placebo for Delirium and Agitation. Completed, enrolled 168 participants across 1 site.

Detailed Summary

The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDelirium, Agitation
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 23, 2017
Enrollment StartDec 21, 2017
Primary CompletionMay 21, 2021
Study CompletionFeb 23, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.7 years ago

Interventions

Dexmedetomidinedrug

The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure

Placeboother

The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure